| Returns | 1W : 2.1% , 1M : -5.8%,1Y : 65.5% |
| Peers & Returns | 1W | 1M | 1Y |
| DR REDDYS LABORATORIES LTD | 2.1% | -5.8% | 65.5% |
| SUN PHARMACEUTICAL INDUSTRIES LTD | -0.2% | 7.6% | 15.4% |
| DIVIS LABORATORIES LTD | 1.1% | 10% | 98.4% |
| CIPLA LTD | -1.4% | -5.1% | 56.5% |
| BIOCON LTD | -0.7% | 1.5% | 64.1% |
| AUROBINDO PHARMA LTD | 2.8% | 7.3% | 97.5% |
| LUPIN LTD | 1.2% | -6.5% | 13.7% |
| TORRENT PHARMACEUTICALS LTD | -2.1% | -0.6% | 46.6% |
| CADILA HEALTHCARE LTD | -2.1% | -0.5% | 67.6% |
| Ratio | Value |
|---|---|
|
P/E P/B P/S |
39.43
P/E Calculated based on EPS of 121.9
[ Mar2020 - Consolidated Results ] 5.16
P/B Calculated based on Book Value of 932.31
[ Mar2020 - Consolidated Results ] 4.42
P/S Calculated based on Revenues of 18085.3 Cr
[ TTM - Consolidated Results ] |
| Model | Discount(-)/ Premium(+) |
|---|---|
|
EV/EBIDTA EV/Sales Price/Sales |
122% 42% 46% |
| Year | Debt/Equity ratio | |
|---|---|---|
|
Debt/Equity ratio analysis
For all non-Banking industries, Good = Ratio less than 0.4 Average = Ratio between 0.4 and 0.6 Bad = Ratio greater than 0.6 Worst is considered between Standalone & Consolidated |
Standalone | Consolidated |
|
2020 2019 2018 Avg_3yrs |
0.1 0.08 0.22 0.13 |
0.14 0.28 0.41 0.28 |
|
[Last Annual Data : Mar2020]
|
||
| Pledged Shares |
0 % |
|---|---|
| As on : Sep2020 | |
If less than 25% | Good |
| If between 25% and 50% | Neutral |
| If greater than 50% | Bad |
| Consolidated | 1 Qtr Growth | 4 Qtr Growth |
|---|---|---|
|
Revenue Op Profit EBIDT Net Income |
10.94% -0.09% -3.05% 30.26% |
2.04% 8.01% 11.78% -30.19% |
| QtrlyTrend |
2
Quarterly Trend analysis
The growth rate score are assigned as under: If ratio's 1Q growth is +ve, then 1. If -ve, then -1. If ratio's 4Q growth is +ve, then 1.If -ve, then -1. Growth Score= Sum of all the above scores for Revenue, Operating Profit and Net Income. Interpretation Good = Growth Score >=4 Neutral = Growth Score between 0 and 4 Bad = Growth Score less than 0 |
|
| Latest Qtr: Sep2020 | ||
